Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Expanded Use of Brain Cancer Device

Expanded Use of Brain Cancer Device News & Analysis News From the Food and Drug Administration Expanded Use of Brain Cancer Device the patients, and the effect lasted between Optune, a portable medical device used to 2.1 and 9.1 months. treat the aggressive brain cancer glioblas- Adverse events from both drugs in- toma multiforme (GBM), has received an ex- cluded fatigue, cough, and decreased appe- panded indication allowing it to be used as tite. In addition, pembrolizumab caused part of standard treatment before the dis- impaired breathing and severe immune- ease progresses (http://1.usa.gov/1jbrVvh). mediatedadverseeffectsinvolvingthelungs, The device initially was approved in 2011 colon, and hormone-producing glands. totreatrecurrenceorprogressionofGBMaf- Nivolumabalsohasthepotentialtocausese- ter chemotherapy. With the expanded indi- vereimmune-mediatedadverseeffects,FDA cation, Optune can be used to treat pa- officials said. tients with newly diagnosed GBM along with the chemotherapy drug temozolomide af- Fast Detection of Central Nervous ter standard treatment that includes sur- System Infections gery and radiation therapy. The device uses A newly approved diagnostic tool is the first nucleic acid–based test capable of quickly electrodes placed directly against the scalp ing to important advances in medicine,” to deliver low-intensity, alternating electri- Richard Pazdur, MD, director of the office of detecting more than 2 dozen pathogens from a small sample http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Expanded Use of Brain Cancer Device

Voelker, Rebecca
JAMA , Volume 314 (19) – Nov 17, 2015
Download PDF
1 page

Expanded Use of Brain Cancer Device

Abstract

News & Analysis News From the Food and Drug Administration Expanded Use of Brain Cancer Device the patients, and the effect lasted between Optune, a portable medical device used to 2.1 and 9.1 months. treat the aggressive brain cancer glioblas- Adverse events from both drugs in- toma multiforme (GBM), has received an ex- cluded fatigue, cough, and decreased appe- panded indication allowing it to be used as tite. In addition, pembrolizumab caused part of standard treatment before the dis-...
Loading next page...
 
/lp/american-medical-association/expanded-use-of-brain-cancer-device-o3NLEQrqWP

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2015.15447
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Expanded Use of Brain Cancer Device the patients, and the effect lasted between Optune, a portable medical device used to 2.1 and 9.1 months. treat the aggressive brain cancer glioblas- Adverse events from both drugs in- toma multiforme (GBM), has received an ex- cluded fatigue, cough, and decreased appe- panded indication allowing it to be used as tite. In addition, pembrolizumab caused part of standard treatment before the dis- impaired breathing and severe immune- ease progresses (http://1.usa.gov/1jbrVvh). mediatedadverseeffectsinvolvingthelungs, The device initially was approved in 2011 colon, and hormone-producing glands. totreatrecurrenceorprogressionofGBMaf- Nivolumabalsohasthepotentialtocausese- ter chemotherapy. With the expanded indi- vereimmune-mediatedadverseeffects,FDA cation, Optune can be used to treat pa- officials said. tients with newly diagnosed GBM along with the chemotherapy drug temozolomide af- Fast Detection of Central Nervous ter standard treatment that includes sur- System Infections gery and radiation therapy. The device uses A newly approved diagnostic tool is the first nucleic acid–based test capable of quickly electrodes placed directly against the scalp ing to important advances in medicine,” to deliver low-intensity, alternating electri- Richard Pazdur, MD, director of the office of detecting more than 2 dozen pathogens from a small sample

Journal

JAMA – American Medical Association

Published: Nov 17, 2015

There are no references for this article.